Evidence map›Paper›PMID 32215717›Full record

ArticleEuropean journal of nutrition2021

Sulforaphane and iberin are potent epigenetic modulators of histone acetylation and methylation in malignant melanoma.

Melina Mitsiogianni, Dimitrios T Trafalis, Rodrigo Franco, Vasilis Zoumpourlis, Aglaia Pappa, Mihalis I Panayiotidis

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nutrition, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 4 countries.

Melina MitsiogianniFaculty of Health and Life Sciences, Department of Applied Sciences, Group of Translational Biosciences, Northumbria University, Newcastle Upon Tyne, NE1 8ST, UK.
Dimitrios T TrafalisLaboratory of Pharmacology, Clinical Pharmacology Unit, Medical School, National and Kapodistrian University of Athens, 11527, Athens, Greece.
Rodrigo FrancoRedox Biology Centre, University of Nebraska-Lincoln, Lincoln, NE, 68588, USA.
Vasilis ZoumpourlisInstitute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, 11635, Athens, Greece.
Aglaia PappaDepartment of Molecular Biology and Genetics, Democritus University of Thrace, 68100, Alexandroupolis, Greece.
Mihalis I PanayiotidisFaculty of Health and Life Sciences, Department of Applied Sciences, Group of Translational Biosciences, Northumbria University, Newcastle Upon Tyne, NE1 8ST, UK. mihalisp@cing.ac.cy.
Cyprus Institute of Neurology and Genetics · CYDemocritus University of Thrace · GRNational and Kapodistrian University of Athens · GRNational Hellenic Research Foundation · GRNorthumbria University · GBUniversity of Nebraska–Lincoln · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

OBJECTIVE(S): Growing evidence supports that isothiocyanates exert a wide range of bioactivities amongst of which is their capacity to interact with the epigenetic machinery in various cancers including melanoma. Our aim was to characterise the effect of sulforaphane and iberin on histone acetylation and methylation as a potential anti-melanoma strategy.

methodsWe have utilised an in vitro model of malignant melanoma [consisting of human (A375, Hs294T, VMM1) and murine (B16F-10) melanoma cell lines as well as a non-melanoma (A431) and a non-tumorigenic immortalised keratinocyte (HaCaT) cell line] exposed to sulforaphane or iberin. Cell viability was evaluated by the Alamar blue assay whilst total histone deacetylases and acetyltransferases activities were determined by the Epigenase HDAC Activity/Inhibition and EpiQuik HAT Activity/Inhibition assay kits, respectively. The expression levels of specific histone deacetylases and acetyltransferases together with those of lysine acetylation and methylation marks were obtained by western immunoblotting.

resultsOverall, both sulforaphane and iberin were able to (1) reduce cell viability, (2) decrease total histone deacetylase activity and (3) modulate the expression levels of various histone deacetylases as well as acetyl and methyl transferases thus modulating the acetylation and methylation status of specific lysine residues on histones 3 and 4 in malignant melanoma cells.

conclusionsOur findings highlight novel insights as to how sulforaphane and iberin differentially regulate the epigenetic response in ways compatible with their anticancer action in malignant melanoma.

Indexed as

HistonesMelanomaAcetylationAnimalsCell Line, TumorEpigenesis, GeneticHistone AcetyltransferasesHumansIsothiocyanatesMethylationMiceSulfoxidesHistone AcetyltransferasesHistonesiberinIsothiocyanatessulforaphaneSulfoxidesAcetyl transferasesDeacetylasesEpigeneticsIberinIsothiocyanatesLysine acetylationLysine methylationMelanomaMethyl transferasesSulforaphane

Identifiers

PMID32215717
OpenAlexW3013565617

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.